Acute Myeloid Leukemia Therapeutics Market Share, Analysis and Segments 2017-2021
Acute myeloid leukemia therapeutics market is rich with branded as well as generic drugs classified under various classes including antineoplastic agents, corticosteroids, tyrosine kinase inhibitors, and others. Cerubidine (daunorubicin), Adriamycin (doxorubicin), Idamycin (idarubicin) and Cytosar (cytarabine) are currently approved drugs in the acute myeloid leukemia market. Clenegen has a strong pipeline for acute mueloid leukemia. CC-486 is currently in phase 3, durvalumaba is currently in phase 2 trials for treatment of acute mueloid leukemia. ImmunoGen, Inc. is also conducting phase 1 trials for IMGN779. Seattle Genetics? SGN-CD33A is also in phase 3 trials for treatment of AML. In 2016, Jazz Pharmaceutical announced initiation of NDA submission for Vyxeos (cytarabine and daunorubicin liposome injection) or CPX-351. The drug was granted breakthrough designation in 2016 for treatment of adults with AML. Vyxeos was also granted orphan drug status by the U.S. FDA and the European Commission for the treatment of acute myeloid leukemia. With these new additions, the acute myeloid leukemia market would grow rapidly in the future.
Request Free Report Sample@ http://www.sa-brc.com/Global-Acute-Myeloid-Leukemia-Therapeutics-Market-Assessment--Forecast-2017-2021/up96
According to statistics published by the Leukemia & Lymphoma Society (LLS), more than 60,000 were expected to be diagnosed with leukemia, of which over 24,000 would die due to the cancer. Cancer Research U.K. estimates more than 9,000 new cases of leukemia in U.K., which accounts for 3% of all cancer cases. The institute also states that the incidence rate has increased by 15% since the early 1990s. The cancer is more prevalent in elderly as compared to young age. Hence with global aging population, it is expected that the prevalence would increase considerably in the future. This would directly result in increased need of therapeutic drugs, potentially driving the acute myeloid leukemia therapeutics market.
Advancing medical technology with deeper insights to cancer genomics has led to cognizance of key biomarkers that play important role in cancer development and progression. With this understanding, scientists have been able to develop targeted therapy that has revolutionized acute myeloid leukemia therapeutics market. These tests guide in selecting most appropriate therapeutic regimen.
Key players in the acute myeloid leukemia therapeutics market include GlaxoSmithKline Pharmaceuticals Limited, Novartis International AG, Bristol-Myers Squibb, Biogen Idec, Pfizer Inc. and others.
Request For TOC@ http://www.sa-brc.com/Global-Acute-Myeloid-Leukemia-Therapeutics-Market-Assessment--Forecast-2017-2021/upcomingdetail96
NOTE: This report is currently under research and will be made available to clients on request.
Spearhead Acuity Business Research & Consulting Private Limited (SA-BRC) is a premium Life Science business intelligence and data analytics firm. SA-BRC team offers a wide range of business intelligence services to multiple stakeholders such as Medical Device Manufacturers, Service Providers (Hospitals, Payers, etc.), Suppliers, Group Purchase Organizations, Distributors and all other individuals in the entire value chain of healthcare industry. Our research and consulting capabilities extend across several sub-domains within the sphere of Life Sciences such as Biotechnology, Healthcare IT, Medical Devices, Veterinary Sciences, Wellness Products and Pharmaceuticals.
Office No. 14,
Hermes Kunj, Mangaldas Road,
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Acute Myeloid Leukemia Therapeutics Market Share, Analysis and Segments 2017-2021 here
News-ID: 637505 • Views: 849
More Releases from SA-BRC
Biochip Market Analysis by Application and Trend 2017-2021
Biochips allow simultaneous testing of higher number of analytes to achieve high throughput and low cost per test. Nanotechnology has helped in miniaturization of devices to achieve higher performance standards. Microarrays are most important part of biochips which send signals to the biochip to deliver end results. Microfluidic biochips have become modern alternative to routine laboratories. Microfluidic technology which enables controlling flow of liquids in micro and pico quantities has
Companion Diagnostics Market Share, Trends Analysis: 2017-2021
Companion diagnostics has revolutionized cancer therapeutics and enabled physicians to select specific treatment pattern from of myriad of drugs for cancer treatment. This has improved treatment outcome manyfold and has now become and indispensable part of personalized medicine. The companion diagnostics market received great attention post success of Herceptin (trastuzumab) and Gleevec (imatinib). Rapid adoption of companion diagnostics and supportive regulatory agencies have encouraged researchers to seek molecules that target
North America and Europe Bionic Eye Market Segment Analysis And Forecast: 2017-2 …
Sudden surge in bionic eye market was experienced recently after the National Health Service (NHS) announced the sponsorship to implant bionic eyes in ten patients. The bionic eye can help regain vision in individuals with visual impairment. Although currently two bionic eye systems has received regulatory approvals, other companies in the bionic eye market are also trying to develop new technology that can help in regaining visual sense in patients. The
Global Antidiabetic Drugs Market - Product Segment Analysis And Forecast
Diabetes is a major lifestyle disorder affecting millions of individuals globally. The disorder is also linked with other complications such as diabetic retinopathy, diabetic foot ulcers, nephropathy and cardiovascular complications among others. Wide spread global prevalence and rising incidence rate has made the antidiabetic drugs market attractive for pharmaceutical drug manufacturers. Introduction of superior products in the recent past and increasing patient compliance are other factors driving the diabetes treatment
More Releases for Acute
Honeywell, Abbott Laboratories, Medtronic, Omron, Acute Technology
The latest report published by ReportsnReports has titled Global Smart Wearable Fitness Devices Sensors Market by Application, By Region and Key Participants - Market Status and Outlook, Competition landscape, share, growth rate, future trends, Opportunities and challenges. Download Free PDF Sample Brochure of report Smart Wearable Fitness Devices Sensors Market spread across 121 pages and supported with tables and figures is now available @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=3090434 The major players in the market include
Acute Myeloid Leukemia Market Growth by 2021
Acute Myeloid Leukemia (AML) is classed as an orphans disease. AML is a rare but a severe disease and is a most common leukemia. It is primarily a disease of the elderly, with an average age of diagnosis of approximately 66. AML results from the acquired changes in the DNA of a developing marrow cell. The marrow cells get converted into the leukemic cells, multiplies into 11 billion or more.
Acute Leukemia Therapeutics Pipeline Analysis
Acute leukemia is also known as cancer of blood cells in which immature blood cells modify into cancer cells. The disease arises from bone marrow and causes formation of numerous large blood cells. Leukemia is categorized into five different types namely acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, and hairy cell leukemia. Leukemia can produce be symptoms such as fever, recurrent nosebleeds, bone pain, swollen
Acute Lung Injury Market Technological breakthroughs 2025
Acute lung injury (ALI) is commonly characterized by hypoxia, lung complication and pulmonary edema. This condition causes inflammation or direct injury to the lungs. Generally, the symptoms of this disease are divided into two forms namely, primary ALI and secondary ALI. Primary ALI is caused by the conditions like pneumonia. While, secondary ALI is mainly caused by indirect injury to the lungs. Inhalation injury, pulmonary contusions, sever trauma, shock are
Acute Renal Failure Epidemiology Insights to 2025
Publisher " Acute Renal Failure ARF Acute Kidney Injury - Epidemiology Forecast To 2025" provides an overview of the epidemiology trends of Acute Renal Failure ARF Acute Kidney Injury in seven major markets US, France, Germany, Italy, Spain, UK and Japan. It includes 10 years epidemiology historical and forecasted data of Acute Renal Failure ARF Acute Kidney Injury prevalent or incident cases segmented by age, sex and subpopulations. The Report
Acute Renal Failure (ARF) (Acute Kidney Injury) Pipeline Review, H2
Market Research Hub (MRH) has recently announced the addition of a fresh report, titled “Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2017” to its report offerings. The report covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1230595 Acute kidney failure occurs when kidneys suddenly become unable to filter waste products from blood.